Tige Rustad
About Tige Rustad
Tige Rustad is a Principal Scientist at Bristol Myers Squibb and a Bioinformatics Scientist at Juno Therapeutics, Inc., with extensive experience in bioinformatics and gene editing.
Current Positions
Tige Rustad currently holds dual roles in the bioinformatics field. As a Principal Scientist at Bristol Myers Squibb in Seattle, Washington, Rustad develops Python and R-based analytic tools for assessing CRISPR editing efficiency. He is a crucial member of the NGS Gene Editing team, focusing on the safety and quality of cell-based therapies. Additionally, Rustad serves as a Bioinformatics Scientist at Juno Therapeutics, Inc., also in the Greater Seattle Area.
Academic Background
Tige Rustad has a robust academic background from the University of Washington. He earned a Bachelor of Science (B.S.) in Biochemistry from 1992 to 1996. He continued his education at the same institution, specializing in Pathobiology for his Doctor of Philosophy (Ph.D.), which he obtained between 1998 and 2003. His academic training provided a strong foundation for his subsequent research and professional roles.
Past Academic Roles
Before transitioning to industry, Tige Rustad was actively engaged in academia. He served as an Affiliate Assistant Professor at the University of Washington from 2017 to 2019. Earlier, he had been a Postdoctoral Fellow at the same institution from 2005 to 2007. These positions allowed him to deepen his research skills and contribute to the academic community.
Experience at Seattle Biomedical Research Institute
Tige Rustad spent a significant portion of his career at the Seattle Biomedical Research Institute. He joined the institute as a Staff Scientist from 2007 to 2009. Subsequently, he was promoted to Senior Scientist, a role he held from 2007 to 2019. During his tenure, Rustad honed his skills in generating and analyzing large biological data sets using R, Unix, Excel, and Python.
Transition from Academia to Industry
Tige Rustad recently transitioned from an academic to an industry setting. This shift has enabled him to apply his extensive research experience to practical applications in the biotechnology and pharmaceutical sectors. He now focuses on developing cutting-edge analytic tools and contributing to novel gene editing initiatives.